Vaughan David Investments LLC IL increased its position in Pfizer Inc. (NYSE:PFE) by 1.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 784,356 shares of the biopharmaceutical company’s stock after purchasing an additional 9,632 shares during the period. Pfizer accounts for 1.3% of Vaughan David Investments LLC IL’s portfolio, making the stock its 22nd biggest position. Vaughan David Investments LLC IL’s holdings in Pfizer were worth $27,837,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. BlackRock Inc. grew its stake in shares of Pfizer by 2.8% in the fourth quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock worth $16,398,445,000 after acquiring an additional 12,183,218 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Pfizer by 11.9% in the fourth quarter. Bank of New York Mellon Corp now owns 70,738,885 shares of the biopharmaceutical company’s stock worth $2,562,162,000 after acquiring an additional 7,534,957 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Pfizer by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 63,123,777 shares of the biopharmaceutical company’s stock worth $2,281,563,000 after acquiring an additional 1,881,570 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Pfizer by 1.5% in the first quarter. Massachusetts Financial Services Co. MA now owns 61,720,550 shares of the biopharmaceutical company’s stock worth $2,190,462,000 after acquiring an additional 889,094 shares during the last quarter. Finally, Fisher Asset Management LLC grew its stake in shares of Pfizer by 3.6% in the fourth quarter. Fisher Asset Management LLC now owns 36,372,349 shares of the biopharmaceutical company’s stock worth $1,317,407,000 after acquiring an additional 1,251,550 shares during the last quarter. 69.45% of the stock is currently owned by institutional investors.
Get Pfizer alerts:In other Pfizer news, Director W Don Cornwell sold 5,223 shares of the stock in a transaction dated Monday, June 4th. The stock was sold at an average price of $36.40, for a total value of $190,117.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Laurie J. Olson sold 19,000 shares of the stock in a transaction dated Wednesday, June 6th. The shares were sold at an average price of $36.45, for a total value of $692,550.00. Following the completion of the transaction, the executive vice president now directly owns 98,644 shares in the company, valued at approximately $3,595,573.80. The disclosure for this sale can be found here. In the last three months, insiders sold 156,535 shares of company stock worth $5,647,222. 0.06% of the stock is owned by corporate insiders.
Shares of Pfizer opened at $37.11 on Friday, MarketBeat Ratings reports. The firm has a market cap of $216.39 billion, a PE ratio of 14.00, a price-to-earnings-growth ratio of 1.80 and a beta of 0.93. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.98 and a current ratio of 1.27. Pfizer Inc. has a 1 year low of $32.32 and a 1 year high of $39.43.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.03. The firm had revenue of $12.91 billion for the quarter, compared to the consensus estimate of $13.14 billion. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The company’s quarterly revenue was up 1.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.69 earnings per share. research analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 4th. Shareholders of record on Friday, August 3rd will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.66%. The ex-dividend date of this dividend is Thursday, August 2nd. Pfizer’s dividend payout ratio is 51.32%.
A number of equities research analysts have recently commented on the company. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a research note on Tuesday. Cantor Fitzgerald set a $45.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, June 13th. Morgan Stanley reissued a “buy” rating and issued a $43.00 target price on shares of Pfizer in a research note on Monday, June 11th. Credit Suisse Group set a $39.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Monday, June 11th. Finally, Societe Generale reissued a “neutral” rating and issued a $39.00 target price on shares of Pfizer in a research note on Wednesday, May 30th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $40.32.
About Pfizer
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
No comments:
Post a Comment